HomeIONS • NASDAQ
add
Ionis Pharmaceuticals Inc
Previous close
$37.62
Day range
$36.56 - $37.66
Year range
$35.92 - $54.44
Market cap
5.45B USD
Avg Volume
1.02M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Financials
Income Statement
Revenue
Net income
(USD) | Mar 2024info | Y/Y change |
---|---|---|
Revenue | 119.50M | -8.45% |
Operating expense | 52.64M | 15.66% |
Net income | -142.80M | -14.86% |
Net profit margin | -119.50 | -25.46% |
Earnings per share | -0.77 | -13.09% |
EBITDA | -146.33M | -31.90% |
Effective tax rate | -0.05% | — |
Balance Sheet
Total assets
Total liabilities
(USD) | Mar 2024info | Y/Y change |
---|---|---|
Cash and short-term investments | 2.21B | -5.93% |
Total assets | 2.76B | -4.20% |
Total liabilities | 2.47B | 2.87% |
Total equity | 296.52M | — |
Shares outstanding | 145.97M | — |
Price to book | 18.53 | — |
Return on assets | -12.99% | — |
Return on capital | -16.15% | — |
Cash Flow
Net change in cash
(USD) | Mar 2024info | Y/Y change |
---|---|---|
Net income | -142.80M | -14.86% |
Cash from operations | -149.94M | -11.90% |
Cash from investing | 76.10M | 123.37% |
Cash from financing | 23.57M | -95.21% |
Net change in cash | -50.38M | -254.73% |
Free cash flow | -92.63M | 3.45% |
About
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics. The company has three commercially approved medicines: Spinraza, Tegsedi, and Waylivra and has four drugs in pivotal studies: tominersen for Huntington's disease, tofersen for SOD1-ALS, AKCEA-APO-LRx for cardiovascular disease, and AKCEA-TTR-LRx for all forms of TTR amyloidosis.
The company was named Isis Pharmaceuticals until December 2015. Wikipedia
Founded
1989
Headquarters
Website
Employees
927